Dr. Frankel earned his MD from Harvard Medical School and conducted his medicine internship at Yale University. Soon after completing his degree, Dr. Frankel began as a research scientist with the National Institute of Health and later completed his medicine residency and oncology fellowship at Stanford University. He is board certified in internal medicine, medical oncology and hematology. Dr. Frankel is a member of the American Society of Clinical Oncology, American Society of Hematology and American Association of Cancer Research.

Dr. Frankel's main focus is combining the clinical practice of hematology/oncology with an investigative cancer drug development program to better move targeted cancer therapeutics into the clinical setting. He has participated in the development of targeted peptide toxins also called immunotoxins for melanoma, breast cancer, ovarian cancer, leukemia, lymphoma, chronic pain, prostate cancer, and thyroid cancer. He has performed phase I clinical trials for many of these agents. He has over 190 peer-reviewed articles, has edited three books, organized for international symposia and received grants from the American Cancer Society, the Leukemia and Lymphoma Society, NIH and the Van Andel Foundation.

In order to provide our website visitors and registered users with a service tailored to their individual preferences we use cookies to analyse visitor traffic and personalise content. You can learn about our use of cookies by reading our Privacy Policy. We also retain data in relation to our visitors and registered users for internal purposes and for sharing information with our business partners. You can learn about what data of yours we retain, how it is processed, who it is shared with and your right to have your data deleted by reading our Privacy Policy.

If you agree to our use of cookies and the contents of our Privacy Policy please click 'accept'.